HK1204976A1 - Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor b-raf egfr pi3k-alpha - Google Patents

Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor b-raf egfr pi3k-alpha

Info

Publication number
HK1204976A1
HK1204976A1 HK15105815.5A HK15105815A HK1204976A1 HK 1204976 A1 HK1204976 A1 HK 1204976A1 HK 15105815 A HK15105815 A HK 15105815A HK 1204976 A1 HK1204976 A1 HK 1204976A1
Authority
HK
Hong Kong
Prior art keywords
inhibitor
pi3k
alpha
raf
egfr
Prior art date
Application number
HK15105815.5A
Other languages
English (en)
Chinese (zh)
Inventor
Giordano Caponigro
Darrin Stuart
Parseval Laure Moutouh-De
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48980368&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1204976(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1204976A1 publication Critical patent/HK1204976A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK15105815.5A 2012-08-07 2015-06-18 Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor b-raf egfr pi3k-alpha HK1204976A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261680473P 2012-08-07 2012-08-07
PCT/US2013/053619 WO2014025688A1 (en) 2012-08-07 2013-08-05 Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor

Publications (1)

Publication Number Publication Date
HK1204976A1 true HK1204976A1 (en) 2015-12-11

Family

ID=48980368

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15105815.5A HK1204976A1 (en) 2012-08-07 2015-06-18 Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor b-raf egfr pi3k-alpha
HK15110834.2A HK1211831A1 (en) 2012-08-07 2015-11-03 Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor b-raf egfr pi3k

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15110834.2A HK1211831A1 (en) 2012-08-07 2015-11-03 Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor b-raf egfr pi3k

Country Status (39)

Country Link
US (1) US9474754B2 (xx)
EP (2) EP2882440B1 (xx)
JP (3) JP6342396B2 (xx)
KR (1) KR102112885B1 (xx)
CN (1) CN104519887B (xx)
AR (1) AR092045A1 (xx)
AU (1) AU2013299841B8 (xx)
CA (1) CA2879548C (xx)
CL (1) CL2015000294A1 (xx)
CO (1) CO7200273A2 (xx)
CY (1) CY1122143T1 (xx)
DK (1) DK2882440T3 (xx)
EA (1) EA028420B1 (xx)
EC (1) ECSP15008695A (xx)
ES (1) ES2717911T3 (xx)
GT (1) GT201500025A (xx)
HK (2) HK1204976A1 (xx)
HR (1) HRP20190537T1 (xx)
HU (1) HUE042877T2 (xx)
IL (1) IL236934B (xx)
IN (1) IN2015DN00450A (xx)
JO (1) JOP20130236B1 (xx)
LT (1) LT2882440T (xx)
MA (1) MA37829A1 (xx)
MX (1) MX359403B (xx)
MY (1) MY176031A (xx)
NZ (1) NZ703940A (xx)
PE (2) PE20191655A1 (xx)
PH (1) PH12015500246A1 (xx)
PL (1) PL2882440T3 (xx)
PT (1) PT2882440T (xx)
RS (1) RS58734B1 (xx)
SG (1) SG11201500321YA (xx)
SI (1) SI2882440T1 (xx)
TN (1) TN2015000027A1 (xx)
TR (1) TR201904980T4 (xx)
TW (1) TWI607754B (xx)
UA (1) UA115786C2 (xx)
WO (1) WO2014025688A1 (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2882440T3 (pl) * 2012-08-07 2019-07-31 Novartis Ag Kombinacje farmaceutyczne zawierające inhibitor b-raf, inhibitor egfr i opcjonalnie inhibitor pi3k-alfa
MA38522A1 (fr) 2013-03-21 2017-10-31 Novartis Ag Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur.
WO2015145388A2 (en) * 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
ES2686549T3 (es) * 2014-06-16 2018-10-18 Worldwide Innovative Network Método para seleccionar una triterapia personalizada para el tratamiento del cáncer
WO2016193955A1 (en) * 2015-06-04 2016-12-08 Giorgio Stassi Combinations of kinase inhibitors for treating colorectal cancer
EP3355886A1 (en) * 2015-08-28 2018-08-08 Novartis AG Pharmaceutical combination comprising the pi3k inhibitor alpelisib and the b-raf inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer
JP2018526375A (ja) * 2015-08-28 2018-09-13 ノバルティス アーゲー 組み合わせ療法
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
UA125436C2 (uk) * 2016-06-03 2022-03-09 Еррей Біофарма, Інк. Фармацевтичні комбінації
WO2018051306A1 (en) * 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
SG11201913249SA (en) * 2017-08-03 2020-02-27 Novartis Ag Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor
FI3860998T3 (fi) 2018-10-05 2024-03-27 Annapurna Bio Inc Yhdisteitä ja koostumuksia apj-reseptorin aktiivisuuteen liittyvien tautitilojen hoitoon
TW202043225A (zh) * 2019-01-25 2020-12-01 英屬開曼群島商百濟神州有限公司 B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途
WO2020164997A1 (en) * 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
WO2023145530A1 (ja) * 2022-01-27 2023-08-03 国立大学法人東北大学 癌治療剤
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2024073364A1 (en) * 2022-09-26 2024-04-04 Beigene, Ltd. Combinations of a b-raf inhibitor, and an anti-egfr antibody for the treatment of cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ME00936B (me) 2007-04-10 2012-06-20 Exelixis Inc Postupci liječenja kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
SG10201402917XA (en) * 2009-08-24 2014-08-28 Genentech Inc Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels
JO3002B1 (ar) * 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
CA2777561A1 (en) * 2009-10-12 2011-04-21 Glaxosmithkline Llc Combination
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
CN105412105A (zh) * 2010-11-08 2016-03-23 诺华有限公司 2-甲酰胺环氨基尿素衍生物在治疗egfr依赖性疾病或对靶向egfr家族成员的药剂有获得性耐受性的疾病中的应用
WO2013070998A1 (en) 2011-11-10 2013-05-16 Memorial Sloan-Kettering Cancer Center TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES
AU2012335663B2 (en) * 2011-11-11 2015-12-24 Array Biopharma Inc. Method of treating a proliferative disease
PL2882440T3 (pl) * 2012-08-07 2019-07-31 Novartis Ag Kombinacje farmaceutyczne zawierające inhibitor b-raf, inhibitor egfr i opcjonalnie inhibitor pi3k-alfa

Also Published As

Publication number Publication date
BR112015002384A2 (pt) 2017-07-04
JP2018109022A (ja) 2018-07-12
MX359403B (es) 2018-09-26
JOP20130236B1 (ar) 2021-08-17
KR20150040905A (ko) 2015-04-15
CY1122143T1 (el) 2020-11-25
EP2882440B1 (en) 2019-02-27
JP6974669B2 (ja) 2021-12-01
PT2882440T (pt) 2019-04-23
RS58734B1 (sr) 2019-06-28
CO7200273A2 (es) 2015-02-27
AU2013299841B8 (en) 2017-01-05
PE20191655A1 (es) 2019-11-07
CN104519887A (zh) 2015-04-15
JP6595024B2 (ja) 2019-10-23
DK2882440T3 (da) 2019-05-06
US9474754B2 (en) 2016-10-25
CN104519887B (zh) 2017-06-27
PH12015500246B1 (en) 2015-03-30
HRP20190537T1 (hr) 2019-06-28
GT201500025A (es) 2017-09-28
TW201410247A (zh) 2014-03-16
HUE042877T2 (hu) 2019-07-29
SG11201500321YA (en) 2015-04-29
EP2882440A1 (en) 2015-06-17
PL2882440T3 (pl) 2019-07-31
MA37829A1 (fr) 2017-01-31
WO2014025688A1 (en) 2014-02-13
MX2015001732A (es) 2015-06-03
BR112015002384A8 (pt) 2019-07-30
IN2015DN00450A (xx) 2015-06-26
IL236934B (en) 2018-11-29
AU2013299841A1 (en) 2015-02-12
PE20150673A1 (es) 2015-05-20
CA2879548C (en) 2020-07-21
ES2717911T3 (es) 2019-06-26
JP6342396B2 (ja) 2018-06-13
UA115786C2 (uk) 2017-12-26
ECSP15008695A (es) 2019-03-29
TN2015000027A1 (en) 2016-06-29
LT2882440T (lt) 2019-04-25
CL2015000294A1 (es) 2015-05-08
CA2879548A1 (en) 2014-02-13
EP3574904A1 (en) 2019-12-04
TR201904980T4 (tr) 2019-05-21
AR092045A1 (es) 2015-03-18
AU2013299841A8 (en) 2017-01-05
SI2882440T1 (sl) 2019-05-31
TWI607754B (zh) 2017-12-11
EA201590332A1 (ru) 2015-06-30
JP2020019780A (ja) 2020-02-06
US20150265616A1 (en) 2015-09-24
HK1211831A1 (en) 2016-06-03
AU2013299841B2 (en) 2016-11-24
MY176031A (en) 2020-07-22
PH12015500246A1 (en) 2015-03-30
KR102112885B1 (ko) 2020-05-19
NZ703940A (en) 2018-04-27
EA028420B1 (ru) 2017-11-30
JP2015524472A (ja) 2015-08-24

Similar Documents

Publication Publication Date Title
HK1204976A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor b-raf egfr pi3k-alpha
HK1202545A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
HK1206795A1 (en) Rapid aneuploidy detection
GB201218801D0 (en) Device,method and software
GB2500915B (en) Arrangement and method
EP2821748A4 (en) DEVICE FOR FINDING A BEACH AND METHOD FOR FINDING A BEACH
PL2831055T3 (pl) Zdolne do polimeryzacji alkilideno-1,3-dioksolan-2-ony i ich zastosowanie
GB201906245D0 (en) A method and device
EP2893664A4 (en) METHOD AND ARRANGEMENTS FOR A TEST SEQUENCE
HK1183362A1 (zh) 查詢方法和裝置
HK1200396A1 (zh) 攪拌裝置以及具備其的吐出裝置和吐出方法
EP2903772A4 (en) MATERIALS, METHODS AND DEVICES FOR CONNECTING LINES
ZA201206179B (en) Software fingerprinting
HK1210930A1 (en) A device and a method for anastomosis
TWI562080B (en) Systes and methods for operation activation
EP2837627A4 (en) AMIDOPYRIDINE DERIVATIVE AND USE THEREOF
EP2808387A4 (en) OLIGONUCLEOTIDE FOR HIV IDENTIFICATION, HIV IDENTIFICATION KIT AND HIV PROOF PROCEDURE
EP2836857A4 (en) COUPLER, PROCESS AND APPLICATIONS
AU2013200291A1 (en) Methods and devices for context set selection
EP2821964A4 (en) COLOR SCALE DETERMINING DEVICE, COLOR SCANNING DETERMINING METHOD, AND COLOR SCANNING DETERMINING PROGRAM
EP2852079A4 (en) RECEIVING DEVICE AND RECEIVING METHOD
EP2869486A4 (en) RECEIVING DEVICE, METHOD, AND PROGRAM
AU2012902452A0 (en) A Review and Challenge System
GB201222541D0 (en) Kiddibidet and pottibidet
IL218974A0 (en) Conaction bitwen coutch and playels